SCHEMBL2260307

SCHEMBL2260307

Cc1ccc(-c2cc(C(=O)O)cc(N3CCOCC3)n2)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.50
PIK3CG P48736 3/20 0.50
AKT1 P31749 2/20 0.44
MTOR P42345 1/20 0.44
ALDH1A1 P00352 4/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 4/20 0.43
PKM P14618 1/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
KMT2A Q03164 2/20 0.42
ADRB2 P07550 1/20 0.42
HIF1A Q16665 2/20 0.41
AR P10275 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2260701 0.88 PIK3CA (0.51) PIK3CAPIK3CGAKT1MTORALDH1A1
SCHEMBL2259992 0.78 NPC1 (0.38) PIK3CAPIK3CGAKT1KDM4ERAB9A
SCHEMBL16440127 0.78 NPC1 (0.38) PIK3CAPIK3CGAKT1KDM4ERAB9A
SCHEMBL3659347 0.77 KMO (0.49) PIK3CAALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL3276269 0.75 PIK3CA (0.58) PIK3CAPIK3CGALDH1A1HPGDSMN1; SMN2
SCHEMBL23259440 0.74 MAPT (0.54) PIK3CAPIK3CGAKT1MTORALDH1A1
SCHEMBL23259436 0.72 MAPT (0.55) PIK3CAPIK3CGAKT1MTORALDH1A1
SCHEMBL2397793 0.70 PIK3CA (0.58) PIK3CAPIK3CGAKT1MTORALDH1A1
SCHEMBL6826440 0.70 CDK1 (0.55) PIK3CAAKT1MTORALDH1A1LMNA
SCHEMBL1442673 0.67 KCNH2 (0.48) PIK3CAPIK3CGMTORALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2860178-B1 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME (US) 2021-01-13 EP disclosed
EP-2860178-A2 P2X3 receptor antagonists for treatment of pain Merck Sharp & Dohme Corp. (US) 2015-04-15 EP disclosed
EP-2358371-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2015-02-11 EP disclosed
US-8598209-B2 P2X3, receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2013-12-03 US disclosed
US-20110206783-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2011-08-25 US disclosed
EP-2358371-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2011-08-24 EP disclosed
WO-2010051188-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206783-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 PIK3CA 1308/4885PIK3CG 1425/4885AKT1 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.